Alternative Splicing and Tumor Progression

被引：131

作者：

Ghigna, Claudia ^{[1
]}

Valacca, Cristina ^{[1
]}

Biamonti, Giuseppe ^{[1
]}

机构：

[1] CNR, Ist Genet Mol, I-27100 Pavia, Italy

来源：

CURRENT GENOMICS | 2008年 / 9卷 / 08期

关键词：

Alternative splicing; cancer; EMT; splicing correction; splicing factors; biomarkers;

D O I：

10.2174/138920208786847971

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Alternative splicing is a key molecular mechanism for increasing the functional diversity of the eukaryotic proteomes. A large body of experimental data implicates aberrant splicing in various human diseases, including cancer. Both mutations in cis-acting splicing elements and alterations in the expression and/or activity of splicing regulatory factors drastically affect the splicing profile of many cancer-associated genes. In addition, the splicing profile of several cancer-associated genes is altered in particular types of cancer arguing for a direct role of specific splicing isoforms in tumor progression. Deciphering the mechanisms underlying aberrant splicing in cancer may prove crucial to understand how splicing machinery is controlled and integrated with other cellular processes, in particular transcription and signaling pathways. Moreover, the characterization of splicing deregulation in cancer will lead to a better comprehension of malignant transformation. Cancer-associated alternative splicing variants may be new tools for the diagnosis and classification of cancers and could be the targets for innovative therapeutical interventions based on highly selective splicing correction approaches.

引用

页码：556 / 570

页数：15

共 116 条

[81] Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CβII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40 [J].